[Concurrent or sequential treatment for osteoporosis with PTH and alendronates].
PTH is a potent stimulator for both bone resorption and formation. The clinical application of PTH on osteoporosis resulted in marked increase in lumber BMD. However, the BMD in the cortical bone site was decreased by PTH administration. Furthermore, serious reduction of lumber BMD after cessation of PTH has been reported. To resolve these disadvantages of PTH treatment in osteoporosis, concurrent or sequential treatment of PTH and alendronate has been proposed. The results seemed to be promising because those modes of treatments showed significant increase in BMD at all bone sites and there was no withdraw phenomenon on BMDs after the cessation of PTH administration. Thus, the sequential or concurrent treatment of PTH and alendronate may be a powerful tool for the prevention of osteoporosis fracture.